M[yofibroblasts]{.smallcaps}are cells of mesenchymal origin that are characterized by a fibroblastic appearance with some ultrastructural features of muscle cells. First described in wound retraction, they are found in almost all organ systems including the external theca of the ovarian follicle, the pulmonary alveolar septa, and the stromal cells of the rat intestinal villi ([@B26]; [@B47]; [@B19]; [@B24]; [@B61]; [@B60]; [@B10]; [@B56]). They are also implicated in pathological situations, such as liver cirrhosis and kidney glomerular fibrosis (for review see [@B60]). It has been hypothesized that myofibroblasts have specialized contractile properties in vivo since they can contract in response to endothelin 1 (ET-1),^1^ a vasoconstrictive peptide that is activated during injury ([@B29]; [@B41]).

The myofibroblasts of liver are called stellate cells and are located in the space of Disse, which is the region between the hepatocytes and the sinusoids. They are involved in retinoid metabolism and are the main producers of extracellular matrix proteins ([@B67]; [@B12]). During liver injury, the stellate cells undergo an activation process characterized by a decrease in vitamin A content and an increase in desmin, an intermediate filament protein normally found in muscle. Their close proximity to the endothelial lining of the sinusoids and their contractility in response to ET-1 have led to the hypothesis that they might function as liver pericytes, which are cells that can be found wrapped around capillaries ([@B14]; [@B43]; [@B22]). In the kidney, the mesangial cells located in the glomeruli are myofibroblasts ([@B23]). These myofibroblasts are involved in the generation of mediators of inflammation, synthesis of cytokines, production and breakdown of basement membrane, as well as uptake of macromolecules ([@B16]; [@B35]; [@B34]; [@B45]; Abboud et al., 1991). In addition, they contract and relax in response to vasoactive agents, including ET-1 ([@B59]; [@B58]; [@B3]). Their contractile properties are thought to control the rate of glomerular filtration by changing capillary surface area and to mediate wound healing after glomerular injury.

The expression of sarcomeric proteins has traditionally been thought to be restricted to striated muscle where their assembly into the sarcomere is highly regulated and ordered. Nonmuscle cells express many homologues of sarcomeric proteins, but there is significant sequence divergence between contractile proteins of muscle and nonmuscle cells. For example, nonmuscle myosin and striated muscle myosin are only 50% identical, and can have up to a 10-fold difference in their ATPase activities. In contrast, all eight striated muscle myosins share \>80% amino acid sequence identity (for review see [@B69]). Myofibroblasts have been broadly characterized by their expression of two proteins found in muscle, smooth muscle α-actin and desmin (for review see [@B56]). There have been reports of additional muscle proteins expressed in myofibroblasts. An adult skeletal fast IId MyHC gene was found to be expressed in a liver stellate cell line ([@B43]). In addition, one study has shown that BHK cells, which we propose are kidney myofibroblasts, express several muscle proteins, including titin ([@B57]).

Very little is known about the mechanisms whereby myofibroblasts achieve their contractile properties nor about the components that define their "muscle-like" phenotype. To define and determine how these cells achieve their intermediate phenotype and to define the molecules that confer contractility to these cells, we have characterized two cell lines corresponding to liver and kidney myofibroblasts. The liver stellate cell line was derived from a cirrhotic rat liver, and we present data that BHK cells are a model of glomerular mesangial cells. We found extensive expression of sarcomeric proteins in BHK cells and more limited expression in liver stellate cells. Two myogenic regulators, myogenin and MyoD, appear to be responsible for activating the muscle program of gene expression in these two myofibroblast cell types. We also demonstrate that ET-1 is a potent stimulus of contraction and that this contraction is correlated with a stimulation of striated muscle protein gene expression.

Materials and Methods
=====================

Cell Culture
------------

The liver stellate cell line, 2G, a gift from Dr. M. Rojkind (Albert Einstein College of Medicine, New York), was maintained in MEM supplemented with 10% FBS (HyClone, Logan, UT), penicillin G at 50 U/ml, and streptomycin at 50 μg/ml, 1% MEM nonessential amino acids, 2 mM [l]{.smallcaps}-glutamine. BHK cells were obtained from Dr. R. Goldman (Northwestern University, Chicago, IL) and were grown in DME with 10% tryptose phosphate broth (Sigma Chemical Co., St. Louis, MO), 10% BCS (HyClone), penicillin G at 50 U/ml, and streptomycin at 50 μg/ml. Cells were grown at 37°C in a 5% humidified CO~2~ incubator. Cells were treated for 24 h with ET-1 (Sigma Chemical Co.) at a final concentration of 10^−10^ M and ET-A and ET-B antagonist, PD145065 (Sigma Chemical Co.), at a final concentration of 5 × 10^−7^ M in serum-free medium. Transient transfections were performed using lipofectamine as described by the manufacturer (GIBCO BRL, Gaithersburg, MD). Myosin light chain reporter constructs were a gift from Dr. N. Rosenthal (Harvard Medical School, Cambridge, MA).

Immunochemistry
---------------

Mouse liver was fixed overnight at 4°C in fresh 4% formaldehyde in PBS (171 mM NaCl, 6 mM Na~2~HPO~4~, 6 mM KH~2~PO~4~, and 3 mM KCl). Tissue was embedded in paraffin following standard procedures ([@B68]). 6-μm sections were deparaffinized, blocked overnight at 4°C in 5% normal goat serum (NGS), 2.5% BSA in PBS. HRP-labeled secondary antibody was visualized with 3-amino-9-ethylcarbazole (Vector Labs, Inc., Burlingame, CA). Antibody incubations were performed overnight at 4°C. Sections were counterstained with Gill\'s hematoxylin to visualize nuclei (Vector Labs, Inc.). Coverslips were fixed in 3.7% formaldehyde in PBS for 5 min, permeabilized in ice-cold acetone for 2 min, and then blocked in 10% NGS for 1 h at room temperature. Subsequent antibody incubations were performed for 1 h at room temperature.

Immunoelectron Microscopy
-------------------------

All incubations were performed at 4°C unless otherwise indicated. Cells were grown on coverslips that were washed with cold PBS three times for 5 min each, fixed with 4% paraformaldehyde in PBS for 30 min, and then washed with PBS as above. Cells were permeabilized with 1% Triton X-100 for 1 min, rinsed with PBS, and then free aldehydes were quenched with 0.05% sodium borohydride in PBS for 1 h at 4°C. Cells were again rinsed in PBS, and then blocked overnight at 4°C in 2% NGS in PBS. Cells were washed three times for 5 min each in 1% BSA, 0.05% Tween-20 in PBS (BSA/Tween/PBS). Primary antibody was diluted in 1% BSA, 0.05% Tween-20, and then incubated overnight. Cells were washed three times for 5 min each with BSA/Tween/PBS and incubated for 12--16 h with secondary antibody, 5 nm gold-conjugated, goat anti--mouse IgG (Ted Pella, Redding, CA). Cells were then washed with 0.05% Tween-20 in PBS, five times for 10 min at room temperature. Cells were then washed in 0.1 M sodium cacodylate, pH 7.4, and postfixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate. Coverslips were removed from the culture dishes for embedding, staining, and sectioning as previously described ([@B32]; [@B55]). Serial sections were cut parallel to the plane of the substratum, and examined in an electron microscope (100C; JEOL USA Inc., Peabody, MA) at an accelerating voltage of 80 kV.

Immunoblot Analysis
-------------------

Protein expression of liver stellate cells and BHK cells was examined by immunoblotting. 100-mm dishes were washed twice in PBS, scraped in cytoskeletal buffer (50 mM KCl, 10 mM KPO~4~, 2 mM MgCl, 0.5 mM EDTA, 2 mM DTT), and then lysed by freeze thawing. Lysate was diluted in Laemmli sample buffer ([@B31]). Protein concentration was determined by Bradford assay, and 10 μg of each protein sample were electrophoresed on a 7.5% SDS-PAGE, transferred to 0.2 μm nitrocellulose membrane (Schleicher and Schuell, Keene, NH), and then membrane blocked with 5% nonfat milk in PBS for 2 h at room temperature. Electrophoresis and electroblotting followed standard protocols ([@B31]; [@B65]). Primary antibody incubations were performed at 4°C overnight. Secondary antibody incubation was performed at room temperature for 2 h. Immunoreactive proteins were visualized using chemiluminescence (Amersham Corp., Arlington Heights, IL).

Proliferation Assay
-------------------

Cells were plated at density of 7.44 × 10^5^ in 100-mm dishes and maintained in serum-free medium for 24 h and treated with 10^−10^ M ET-1 for 24 h. Cells were trypsinized with 1 ml of trypsin/EDTA and counted with an hemocytometer 24 h after addition of ET-1.

Collagen Contraction Assay
--------------------------

Collagen solution, vitrogen 100 (Celltrix Laboratories, Palo Alto, CA), containing liver stellate cells (2 × 10^5^ cells/ml) or BHK (7.5 × 10^5^ cells/ml) were prepared as previously described ([@B40]), with the exception that 0.5 ml of partially gelled collagen was pipetted into wells containing warm silicon oil instead of 0.1 ml of collagen.

CAT Assays on Cultured Cell Lysates
-----------------------------------

Transient transfections were performed using lipofectamine as described by the manufacturer (GIBCO BRL). 48 h after transfections, dishes were washed three times in PBS. Cell lysate was prepared by freeze thawing. The amount of protein in the supernatant was measured by the Bradford assay using BSA as the standard (Bio-Rad Laboratories, Hercules, CA). chloramphenicol acetyl transferase (CAT) assays were performed on 10 μg of total protein. CAT assays were done by TLC with an incubation for 2 h at 37°C ([@B20]).

Antibodies
----------

Primary monoclonal antibodies were F59 ([@B36]), antiembryonic myosin heavy chain, F.1652 (a gift from Dr. H. Blau, Stanford University School of Medicine, Palo Alto, CA), antiperinatal myosin heavy chain, N3.36 (a gift from Dr. H. Blau), anti-MyoD and antimyogenin (Novocastra, Burlingame, CA), antisarcomeric actin, HUC1-1 (a gift from Dr. J. Lessard, University of Cincinnati, Cincinnati, OH), anti-myosin light chain (MLC) 1,3 (a gift from Dr. F. Stockdale, Stanford University School of Medicine). Monoclonal antibodies against tropomyosin, troponin T (TnT), desmin, and titin were purchased from Sigma Chemical Co. Secondary antibodies conjugated to fluorescein and HRP were obtained from Jackson Immunoresearch Laboratories (West Grove, PA). Actin was visualized with rhodamine phalloidin (Molecular Probes, Eugene, OR).

Results
=======

Expression of Sarcomeric Proteins in BHK and Liver Stellate Cells
-----------------------------------------------------------------

Previous reports of the expression of muscle proteins in myofibroblasts (Table [I](#TI){ref-type="table"}) led us to determine the extent of sarcomeric protein gene expression in both BHK and liver stellate cells by immunocytochemistry and Western blotting using isoform-specific antibodies. In addition to expressing smooth muscle α-actin and desmin, they also express many skeletal muscle structural proteins (Table [I](#TI){ref-type="table"}). Both the number and category are different between the two myofibroblast cell types. As shown in Table [I](#TI){ref-type="table"}, the liver stellate cells express three skeletal muscle myosin heavy chain isoforms (MyHCs) including one developmental isoform and two adult isoforms. To confirm that sarcomeric proteins are expressed in vivo in liver myofibroblasts, serial sections from a mouse liver were stained with a sarcomeric MyHC antibody. As shown in Fig. [1](#F1){ref-type="fig"}, the staining is localized to the liver stellate cells.

BHK cells express the entire program of developmental and adult skeletal MyHC isoforms tested thus far. Neither cell line expresses α-cardiac MyHC, which suggests that only the skeletal muscle program is activated in these two myofibroblast cell types. Unlike the liver stellate cell line, the BHK cell line also expresses sarcomeric thin filament proteins, including α and β tropomyosin and TnT. To determine whether the expression of sarcomeric proteins was homogeneous across the cell population, cells were stained with an antibody that recognizes all sarcomeric MyHCs, F59 ([@B36]). Approximately 10% of liver stellate cells expressed sarcomeric MyHC in culture, whereas 30% of BHK cells expressed sarcomeric MyHC under standard growth conditions (Fig. [2](#F2){ref-type="fig"}). In those cells expressing sarcomeric MyHC, the level of expression corresponds to 0.01% of total protein in liver stellate cells and 0.1% of total protein in BHK cells. This compares to 0.2--0.5% of total protein for nonmuscle MyHC (data not shown).

To determine whether the sarcomeric MyHC expressed in BHK and liver stellate cells interacts with the nonmuscle cytoskeleton, sarcomeric and nonmuscle MyHC were visualized by double-label immunofluorescence. There was no colocalization of sarcomeric and nonsarcomeric MyHC in liver stellate cells (Fig. [2](#F2){ref-type="fig"}, *a* and *c*), whereas there was some colocalization of the two MyHCs in BHK cells but no appearance of the sarcomeric MyHC in the stress fibers (Fig. [2](#F2){ref-type="fig"}, *b* and *d*). In skeletal muscle, tropomyosin and TnT interact with the actin filaments. To determine the localization of sarcomeric tropomyosin and TnT in BHK cells, double-label immunofluorescence was performed. As shown in Fig. [3](#F3){ref-type="fig"}, there is colocalization of tropomyosin and TnT with the actin filament network of the cell.

Organization of Sarcomeric MyHC in BHK and Liver Stellate Cells
---------------------------------------------------------------

If the expressed sarcomeric MyHC is to play a unique contractile function in these two myofibroblast cell types, it might be expected to be organized into filamentous structures that are distinct from the nonmuscle MyHC. It is well established that muscle and nonmuscle MyHC filaments are very different in size and organization ([@B9]; [@B39]; [@B66]). Sarcomeric thick filaments are 1.5 μm in length and composed of 100--200 MyHC molecules, whereas nonmuscle MyHC is organized into 0.25--0.35-μm minifilaments composed of 16--28 MyHC molecules (for review see [@B30]). To examine the organization of sarcomeric MyHC in BHK and liver stellate cells, immunogold electron microscopy was carried out. Sarcomeric MyHC expressed in BHK and liver stellate cells formed bundles of filaments as determined by immunogold labeling (Fig. [4](#F4){ref-type="fig"}, *a* and *b*) whereas nonmuscle MyHC did not (Fig. [4](#F4){ref-type="fig"}, *c* and *d*). From this analysis, it is clear that there are no sarcomeres in either of these cell lines and there is no apparent periodicity to the structures formed by the muscle MyHC.

Myogenic Regulators Control Sarcomeric Gene Expression in Liver Stellate Cells and BHK Cells in an E-Box--Dependent Manner
--------------------------------------------------------------------------------------------------------------------------

Myogenic regulatory factors (MRFs) are responsible for controlling the expression of muscle-specific genes during development (for review see [@B38]). Since a wide array of "muscle" genes are expressed in myofibroblasts, we hypothesized that myogenic regulators are expressed in BHK and liver stellate cells and are responsible for activation of muscle structural proteins. As determined by immunocytochemistry, MyoD (Fig. [5](#F5){ref-type="fig"}) and myogenin (data not shown) were detected in 100% of BHK and liver stellate cells. Myf-5 was not detected in either cell line (data not shown).

MRFs control muscle gene expression by binding to DNA consensus sequences, called E-boxes, that are found in the control regions of many muscle genes ([@B8]). To determine whether the same programs that regulate gene expression in muscle cells also activate the muscle genes in BHK and liver stellate cells, skeletal myosin light chain (MLC) 1,3 promoter elements linked to the CAT reporter gene (MLC-CAT) were transfected into BHK and liver stellate cells. The wild-type construct, which has three E-boxes, is sufficient to confer muscle-specific gene expression in cultured cells and in transgenic mice, and its activity is dependent on the presence of MRFs ([@B54]; [@B71]). The second construct is mutated in all three E-boxes and is not expressed in muscle cells ([@B71]). Included as a positive cell control were C2C12 myotubes and as negative controls, C2C12 myoblasts, and L cells. As shown in Fig. [6](#F6){ref-type="fig"}, the wild-type MLC construct is as active in BHK and stellate cells as in C2C12 differentiated muscle cells. In addition, the activity of the MLC construct in BHK and liver stellate cells is abolished when the E-boxes are mutated, indicating that the expression of this sarcomeric gene in BHK and liver stellate cells is dependent on the presence of the MRFs.

ET-1--induced Contraction of BHK and Liver Stellate Cells Is Accompanied by an Increase in Sarcomeric MyHC Expression
---------------------------------------------------------------------------------------------------------------------

Tissue repair includes the activation of resident mesenchymal cells to become myofibroblasts and the induction of ET-1 ([@B33]; [@B56]). The activation process involves the development of a contractile phenotype with increased expression of smooth muscle α-actin in vivo ([@B56]; [@B18]). ET-1 has been shown to induce contractility of cultured stellate cells and mesangial cells ([@B3]; [@B53]). To determine if ET-1 can induce the contraction of BHK and the liver stellate cell line characterized here, we performed a collagen contraction assay in the presence and absence of ET-1, using mouse L cells as a negative control. In the absence of exogenously added ET-1, myofibroblasts exhibited limited contractility, while L cells did not. As shown in Fig. [7](#F7){ref-type="fig"}, there was a dramatic contractile response to ET-1 that was blocked by an endothelin antagonist in both liver stellate cells and BHK cells.

To determine if there was a change in sarcomeric MyHC expression in response to ET-1, cells were grown for 24 h in the presence of ET-1 and scored for the proportion of cells expressing MyHC and the amount of MyHC expressed. To confirm that the proportional increase in MyHC, which was visible by immunofluorescence, was accompanied by an increase in the amount of MyHC protein, Western analysis was also performed on the cells in the absence and presence of ET-1. As shown in Fig. [8](#F8){ref-type="fig"}, there was a ninefold increase in the proportion of MyHC-positive stellate cells and a threefold increase in the proportion of sarcomeric, MyHC-positive BHK cells. These increases were accompanied by a significant increase in the amount of sarcomeric MyHC (Fig. [8](#F8){ref-type="fig"}).

Discussion
==========

We believe that the liver stellate cell line and BHK cells are good culture models for the myofibroblasts of the liver and the kidney, respectively. They satisfy the established criteria for myofibroblasts. They actively produce extracellular matrix proteins and express desmin and smooth muscle α-actin ([@B64]; [@B48]; [@B52]). In addition, the cells contract in response to treatment with ET-1. The discovery of extensive sarcomeric protein gene expression is consistent with the idea that these cells may be uniquely equipped for the contractile activities required for wound healing.

A key characteristic of these cells is their expression of sarcomeric myosins. Myosins are the molecular motors responsible for movement in all eukaryotic cells. It seems logical to attribute the acquisition of unique contractile capacity of myofibroblasts to the expression of sarcomeric proteins. Sarcomeric myosin was previously thought to perform a single function, that of muscle contraction in the context of the sarcomere, whereas the myosin expressed in nonmuscle cells has been shown to be involved in diverse cellular functions, ranging from cytokinesis to morphogenesis ([@B13]; [@B17]). Given that many nonmuscle cells actively divide, one requirement for the nonmuscle myosin filaments is that they be able to undergo rounds of assembly and disassembly. The muscle sarcomere is a much more stable structure and most changes in its composition are thought to occur by exchange, in and out, of existing structures ([@B70]). Clearly, the sarcomeric proteins expressed in myofibroblasts are able to function in an actively dividing cell. Sarcomeric MyHC in liver stellate cells and BHK cells is organized differently than the nonmuscle MyHC, but despite the presence of most of the components of the sarcomere in BHK cells, sarcomeres do not form. BHK cells are quite remarkable in that they express every skeletal muscle structural protein we have tested (except titin), including ones that are normally developmentally regulated. As mentioned earlier, there is a report that under certain growth conditions, BHK cells can even express titin ([@B57]). It seems logical that the sarcomeric motor molecules provide unique contractile properties to myofibroblasts during processes such as wound healing.

The activation of the myogenic program in muscle precursor cells involves a number of regulatory factors that regulate the expression of sarcomeric proteins ([@B46]; [@B63]; [@B7]). MyoD, Myf-5, MRF4, and myogenin act as transcriptional activators of many skeletal muscle genes ([@B11]; [@B5]; Rhodes et al., 1989; [@B72]; [@B6]; [@B37]; [@B15]). The expression of MyoD and myogenin in cultured liver stellate cells and BHK cells suggests that the muscle program in these specialized nonmuscle cells is activated by some of the same factors that are used during myogenesis. This is further supported by the transient transfection assays, which indicate that MRF-binding sites in the MLC enhancer are targets for the action of these factors in myofibroblasts. It is very intriguing that these cells express both myogenic regulators and muscle structural proteins, and yet they are not terminally differentiated, nor are they morphologically differentiated. It is also interesting that these two cell types express distinct programs of muscle gene expression, with the liver stellate cells expressing a more limited program. What limits muscle gene expression in liver stellate cells to the thick filament?

The wound healing response is a complex process that involves interplay of extracellular matrix components, cytokines, and biologically active peptides, such as members of the endothelin family ([@B62]; [@B42]). ET-1 is a powerful vasoconstrictive agent synthesized by vascular endothelial cells ([@B73]). Significant amounts of ET-1 are produced by nonendothelial cells such as mesangial cells and liver stellate cells. In the liver, the stellate cells have abundant ET-1 receptors ([@B21]; Rockey et al., 1995). In the kidney, a number of glomerular cells, including the mesangial cells synthesize ET-1 and also express ET receptors ([@B28]; [@B27]). There is an increased level of ET-1 during liver and kidney injury ([@B44]; [@B41]; [@B2]). Cultured liver stellate cells and mesangial cells display increased contractility in response to ET-1 ([@B3]; [@B29]; [@B25]; [@B53]). Furthermore, intravenous injection of ET-1 directly into rat kidneys led to a decrease in glomerular filtration rate and renal blood flow with a concomitant contraction of mesangial cells cultured from the injected rats. These effects were reversed by injection of an anti--ET-1 antibody ([@B29]). Likewise, liver stellate cells treated with ET antagonists showed a decrease in smooth muscle α-actin expression ([@B51]). In this study, we confirm that an established liver stellate cell line and BHK cells can contract in response to ET-1. In addition, we demonstrate that there is a significant increase in the number of cells expressing sarcomeric MyHC. This is additional evidence supporting a functional role for the sarcomeric proteins expressed in these two myofibroblast cell types. This contractile response is not accompanied by an increase in cell proliferation (Mayer, D.H.G., and L.A. Leinwand, unpublished observation). We also demonstrate that the contractility of liver stellate cells and mesangial cells is blocked by the presence of an ET-1 antagonist.

There are numerous questions about these intriguing cells that will form the basis for future investigation. Future experiments will be directed towards identifying pathways that lead to myofibroblast cell types in vivo as well as determining the effects of disrupting sarcomeric protein expression on liver stellate cell and BHK cell contractility. Additionally, it will be interesting to determine the block to terminal differentiation that prevents the full differentiation potential of the myogenic regulators.
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ET-1

:   endothelin 1

MLC

:   myosin light chain

MRF

:   myogenic regulatory factors

MyHC

:   myosin heavy chain isoforms

NGS

:   normal goat serum

TnT

:   troponin T

###### 

Muscle Protein Expression in Myofibroblasts[\*](#TFI-150){ref-type="table-fn"}

                                    In Vivo[‡](#TFI-152){ref-type="table-fn"}      Liver stellate cells      BHK cells      L cells
  ------------------------------ -- ------------------------------------------- -- ---------------------- -- ----------- -- ---------
  Sarcomeric MyHC                                                                  \+                        \+             −
   Embryonic                                                                       −                         \+             −
   Perinatal                                                                       \+                        \+             −
   Adult skeletal fast IIa                                                         \+                        \+             −
   Adult skeletal fast IIb                                                         −                         \+             −
   Adult skeletal fast IId          \+                                             \+                        \+             −
   α-Cardiac MyHC                                                                  −                         −              −
   β MyHC                                                                          −                         \+             −
  Sarcomeric MLC                                                                   −                         \+             −
  Sarcomeric actin                                                                 −                         \+             −
  Sarcomeric tropomyosin (α,β)                                                     −                         \+             −
  Sarcomeric troponin T                                                            −                         \+             −
  Smooth-muscle MyHC                \+                                             \+                        \+             −
  Smooth-muscle actin               \+                                             \+                        \+             −
  Titin                                                                            −                         −              −
  Desmin                            \+                                             \+                        \+             −

 Cells were grown on coverslips under normal growth conditions. Coverslips were fixed and stained as described in Materials and Methods. 100-mm dishes were scraped in Laemmli sample buffer. Lysate was used for immunoblotting.  

 Previous in vivo reports in myofibroblasts ([@B4]; [@B56]; [@B43]).  

![Sarcomeric MyHC is expressed in vivo in liver stellate cells. Immunoperoxidase labeling of sections of liver tissue was performed to visualize liver cell types expressing sarcomeric MyHC by using F59. Only perisinusoidal cells are positive for sarcomeric MyHC (*arrow*). Bar, 10 μm.](JCB.29352f1){#F1}

![Localization of nonmuscle and sarcomeric MyHC expressed in liver stellate cells and BHK cells. Indirect immunofluorescence was performed to visualize MyHC in liver stellate cells (*a* and *c*) and BHK cells (*b* and *d*). Sarcomeric MyHC (*a* and *b*) forms punctate structures around the plasma membrane of liver stellate cells whereas it is more uniformly distributed in the cytoplasm of BHK cells. Sarcomeric (*a* and *b*) and nonmuscle MyHC (*c* and *d*) show partial colocalization in BHK cells, but not in liver stellate cells. Bars, (*a* and *c*) 10 μm, and (*b* and *d*) 20 μm.](JCB.29352f2){#F2}

![Localization of sarcomeric thin filament proteins in BHK cells. Indirect immunofluorescence was performed to localize sarcomeric α and β tropomyosin (*a*), sarcomeric TnT (*c*), and the actin filaments (*b* and *d*) using anti-TnT, antisarcomeric tropomyosin, and rhodamine phalloidin. Sarcomeric TnT and sarcomeric α and β tropomyosin colocalize with the actin filaments. Bar, 10 μm.](JCB.29352f3){#F3}

![Ultrastructural analysis of sarcomeric MyHC in liver stellate cells and BHK cells. Immunoelectron microscopy was performed to determine the organization of sarcomeric MyHC in liver stellate cells and BHK cells. Monoclonal antibody, F59, was used to detect sarcomeric MyHC in liver stellate (*a*) and BHK cells (*b*); anti--α-platelet myosin antibody was used to detect nonmuscle MyHC in liver stellate cells (*c*) and BHK cells (*d*). Secondary antibodies were 5 nm gold-conjugated IgG. Arrows denote areas in inset for *a* and *b.* Bar, 1 μm.](JCB.29352f4){#F4}

![Localization of MyoD in liver stellate cells and BHK cells. Indirect immunofluorescence was performed to localize MyoD in liver stellate cells (*a*) and BHK cells (*b*) using a monoclonal anti-MyoD antibody. MyoD expressed in liver stellate cells and BHK cells has a normal nuclear localization. Bar, 10 μm.](JCB.29352f5){#F5}

![E-box dependent expression of muscle reporter constructs in myofibroblasts. Previously described MLC reporter constructs were transfected into cell types as indicated ([@B71]). CAT activity is corrected for transfection efficiency by using a luciferase construct as a cotransfection reference plasmid. Transfections were carried out in triplicate. CAT activity is presented as mean value ± standard error.](JCB.29352f6){#F6}

![ET-1 dependent contractility of myofibroblasts. Contraction assays were performed as described in Materials and Methods. The change in diameter of the collagen gel was measured after 24 and 48 h in the absence of ET-1 (○) after addition of 10^−10^ M ET-1 (•) and 5 × 10^−7^ M ET-1 antagonist (▾). Each contraction assay was performed in triplicate. Data are presented as mean values ± standard error.](JCB.29352f7){#F7}

![ET-1 increases expression of sarcomeric MyHC in myofibroblasts. (*A*) Indirect immunofluorescence was performed to determine the number of sarcomeric MyHC-positive liver stellate cells and BHK cells before (−) and after (+) treatment with 10^−10^ M ET-1 for 24 h. (*B*) Immunoblotting was performed to determine the increase of sarcomeric MyHC in liver stellate cells and BHK cells in the absence of serum (lane *1*), in the presence of 10% serum (lane *2*), in the presence of 5 × 10^−7^ M ET-1 antagonist (lane *3*), and in the presence of 10^−10^ M ET-1 for 24 h (lane *4*).](JCB.29352f8){#F8}
